Tentative Program

8th World Congress on
Bioavailability and Bioequivalence Pharmaceutical R & D Summit

June 26-27, 2017 San Diego, California, USA



Interactive Sessions | Keynote Lectures | Plenary Lectures | Workshops

Exhibitors | B2B Meetings

For available speaker slots

ba.be@pharmaceuticalconferences.org

8th World Congress on Bioavailability and Bioequivalence Pharmaceutical R & D Summit

conferenceseries.com

June 26-28, 2017 San Diego, USA

Program at a Glance

Day 1

Morning Sessions	**Reception/Registration**	**08.00-09.00**	
		Time	**General Session**
	Least of 3 Keynote/Plenary Talks	09.00-09.15	Inaugural Address
		09.15-09.45	Keynote/Plenary Talk 1
		09.45-10.15	Keynote/Plenary Talk 2
		10.15-10.45	Keynote/Plenary Talk 3
	Panel Discussions/Group Photo		
	Coffee/Tea Break 10.45-11.00 (Networking)		
	11.00-12.40	5 Speakers (20 Mins Each)	
Evening Sessions			
	Lunch Break 12.40-13.30		
	13.30-15.30	6 Speakers (20 Mins Each)	
	Coffee/Tea Break 15.30-15.45 (Networking)		
	15.45-17.25	5 Speakers (20 Mins Each)	

19 Speakers for **Day 1**

Day 2

Morning Sessions	**Time**	**Session 1**	**Session 2**
	09.00-10.40	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Coffee/Tea Break 10.40-10.55 (Networking)		
	10.55-12.35	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Lunch Break 12.35-13.25		
Evening Sessions	**13.25-15.05**	**5 Speakers (20 Mins Each)**	**5 Speakers (20 Mins Each)**
	Poster Sessions		
	Coffee/Tea Break 15.05-15.20 (Networking)		
	15.20-17.00	**5 Speakers (20 Mins Each)**	**5 Speakers (20 Mins Each)**

40 Speakers on **Day 2**

Awards & Closing Ceremony

NOTE: Program Shedule is subject to change with final allotment of the speaker slots

For more Details PS: http://bioavailability-bioequivalence.pharmaceuticalconferences.com

Email: ba.be@pharmaceuticalconferences.org

Conference Highlights

- Significance of BA/BE Studies
- Advances in BABE
- Bioavailability Studies
- Bioequivalence Studies
- Factors Affecting Bioavailability
- Assessment of Bioequivalence
- Managing BA/BE Studies
- Regulatory Requirements for Bioequivalence
- Study Designs
- Bioequivalence Protocols : *In vivo/ In vitro* studies
- Nutrient Bioavailability
- BA/BE of biologics & Biosimilars
- Clinical Trials
- Pharma Clinical Trials
- Contract Research Organizations
- Challenges in Drug Design
- Challenges in Drug Development
- Clinical Pharmacology and Therapeutics
- Pharmaceutical Industry: Entrepreneurs Investment Meet

Best Poster Award

- You will be given about 5-7 minutes to present your poster including questions and answers. Judges may pose questions during the evaluation of the poster
- Judges will even evaluate the student's enthusiasm towards their study, interest and knowledge in the area of their research
- The winners will be announced at the closing ceremony of the conference. The decision of the winner will be withdrawn if the winner/winners is/are not present at the time of announcement



- Apart from the judging time you may also be present at the poster to share your research with interested delegates



Young Researchers Forum

- Present your research through oral presentations
- Learn about career development and the latest research tools and technologies in your field
- This forum will give pertinent and timely information to those who conduct research and those who use and benefit from research
- Develop a foundation for collaboration among young researchers
- The forum will provide an opportunity for collegial interaction with other young investigators and established senior investigators across the globe
- Interact and share ideas with both peers and mentors

General Queries
ba.be@pharmaceuticalconferences.org

Conference Venue

San Diego,California,USA

Contact us
America: Conference Series LLC
BABE 2017
57 Ullswater Avenue, West End, Southampton, Hampshire,
United Kingdom, SO18 3QS
Tel: +1-888-843-8169, Fax: +1-650-618-1417
Email: ba.be@pharmaceuticalconferences.org


Contact us
UK: Conference Series LLC
BABE 2017
40 Bloomsbury Way Bloomsbury Way, Lower Ground Floor, London, England, WC1A 2SE
Tel: +1-800-216-6499
Email: ba.be@pharmaceuticalconferences.org

Contact us
Asia-Pacific: Conference Series LLC
BABE 2017
Divyasree Building, Raidurg
6th Floor, North Block
Hyderabad 500032, INDIA
Tel: 040-33432309
Email: ba.be@pharmaceuticalconferences.org

For detailed sessions, please visit: http://bioavailability-bioequivalence.pharmaceuticalconferences.com/

Submit your abstract online at: http://bioavailability-bioequivalence.pharmaceuticalconferences.com/abstract-submission.php

Register online: https://www.conferenceseries.com/onlinepayment/



Glimpses of BABE Conferences









conferenceseries.com


639th Conference

Scientific Program

7th World Congress on

Bioavailability and Bioequivalence: Pharmaceutical R & D Summit

August 29-31, 2016 Atlanta, USA



Day 1 August 29, 2016

08:30-09:30 Registrations

Hall- Allatoona

conferenceseries.com 09:45-10:05

Opening Ceremony

Keynote Forum

Introduction

Title: Parenteral drug delivery systems for insoluble drugs
Jim Jingjun Huang, Ascendia Pharmaceuticals, USA

Group photo

Networking and Refreshments Break

Title: Hybrid-Nanoengineering™: A new platform for nanomedicine
Mewa Singh, Meda Biotech LLC, USA

Sessions:
Challenges in Drug Development | Bioavailability Studies | Assessment of Bioequivalence | Clinical Pharmacology and Therapeutics

Session Chair: Akwete Lex Adjei, Rhodes Pharmaceuticals L.P, USA
Session Co-chair: Muneesh Garg, Sitec Labs. Pvt. Ltd., India

Session Introduction

Title: New analytical methodology in assessing comparability of biosimilars
Julia Ding, PPD Labs, USA

Lunch Break

Title: Design and synthesis of potential ribonucleotide reductase enzyme (RNR) inhibitors as antileukemic and/or antiviral 2'-deoxymethylene nucleosides
Khairia M Youssef, Future University, Eygpt
Title: Risk assessment with the help of FMEA analysis in BE studies
Kateryna Zupanets, National University of Pharmacy, Ukraine
Title: Some aspects of clinical trials on bioequivalence studies
Kateryna Zupanets, National University of Pharmacy, Ukraine
Title: Bioequivalence of Ipratropium Bromide HFA pMDI 20 µg/ actuation in healthy volunteers with and without charcoal blockade; and with spacer device
Muneesh Garg, Sitec Labs. Pvt. Ltd., India

Networking and Refreshments Break

Title: Prasugrel effect on *In vitro* bleeding time tests in a single dose bioequivalence study
Ahmet Inal, Erciyes University, Turkey
Title: Audits and Inspections - bioavailability and bioequivalence studies
Bipin Patel, RSServe, India
Title: The use of asymmetric distributions in average bioequivalence
Roberto Molina de Souza, University of Parana, Brazil

Panel Discussion

Day 2 August 30, 2016

Hall- Allatoona

Keynote Forum

Title: Steady-state bioavailability of extended-release Methylphenidate capsules vs. immediate-release Methylphenidate tablets in healthy adult volunteers
Akwete Lex Adjei, Rhodes Pharmaceuticals L.P, USA

Networking and Refreshments Break

Sessions:
Clinical Trials | Challenges in Drug Design | Biosimilars

Session Chair: Mewa Singh, Meda Biotech LLC, USA
Session Co-chair: Sue Duran, Auburn University, USA

Session Introduction

Title: Accelerating preclinical development for poorly bioavailable compounds by assessing multiple oral technologies in parallel
Stephen Tindal, Catalent, USA
Title: Starch-guar gum extrudates: Microstructure, physicochemical properties and *in vitro* digestion
Erich von Borries Medrano, Instituto Politecnico Nacional, Mexico

Poster Presentations @ 12:15-12:45

BABE-001
Title: Suggestions for stage I of clinical trials of Diclocor
Oleksii Popov, National University of Pharmacy, Ukraine

BABE-002
Title: Micellar liquid chromatographic determination of Lamivudine, Indinavir and Ketoconazole in dosage forms and biological fluids
Wael Talaat, Damanhour University, Egypt

Lunch Break

Title: Overview of bioavailability/bioequivalence clinical trials in a phase 1 in Turkey
Zafer Sezer, Erciyes University, Turkey
Title: Structural approaches for targeted therapy
Somdutta Saha, GlaxoSmithKline, USA
Title: Development of sustained release antifungal, anti-protozoa and antimicrobial products in horses using hydrogels and extended release formulations in veterinary medicine
Sue Duran, Auburn University, USA

Panel Discussion



Day 1 August 17, 2015

Registrations

Hall-2

Opening Ceremony

Keynote Forum

Introduction

Paramjeet Kaur
U.S. Food and Drug Administration, USA

Workshop
Jim Jingjun Huang
Ascendia Pharmaceuticals, USA

Group Photo

Networking & Refreshments

Track 3: Contemporary Challenges of Drug Design, Discovery and Development
Track 7: Bioavailability, Bioequivalence and Drug Product Selection
Track 11: Clinical Pharmacology and Therapeutics
Track 12: Study Designs

Session Chair: Paramjeet Kaur, U.S. Food and Drug Administration, USA
Session Co-Chair: Aydın Erenmemisoglu, Novagenix Drug R&D Centre, Turkey

Session Introduction

Title: Bioequivalence of topical corticosteroids: Design and data analysis challenges with the vasoconstrictor assay
Keith Gallicano, Novum Pharmaceutical Research Services, USA
Title: Prediction of *in-vivo* permeability, solubility, BCS-classing, food interactions, fraction absorbed and oral bioavailability using new *in-silico* methods and algorithms
Urban Fagerholm, Prosilico, Sweden

Lunch Break

13:50-14:20 **Title: Discovery of novel scaffolds for p^{21}-activated kinase 4 inhibitors targeting C- terminal**
Dongmei Zhao, Shenyang Pharmaceutical University, China

Track 1: Emerging Bioavailability and Bioequivalence Studies
Track 5: Managing BA/BE Studies
Track 9: Need for Conducting BA/BE Studies
Track 13: Factors Affecting Bioavailability

Session Chair: Paramjeet Kaur, U.S. Food and Drug Administration, USA
Session Co-Chair: Aydın Erenmemisoglu, Novagenix Drug R&D Centre, Turkey

Session Introduction

Title: Optimizing formulation to maximize drug absorption from solution formulations
Wenzhan Yang, Astra Zeneca Pharmaceuticals LP, USA
Title: Design, synthesis and studies of delta and Cox-2 receptor specific analgesic anti-inflammatory activity of some linear and cyclic peptides
Subir Samanta, Birla Institute of Technology, India

Networking & Refreshments

Title: The Bioequivalence of Citicoline 500mg film tablet
Onursal Saglam, Novagenix Biyoanalitik Ilac, Turkey
Title: Possible mistakes and manipulations in bioequivalency trials
Aydın Erenmemisoglu, Novagenix Drug R&D Centre, Turkey
Title: Mexico and Brazil: Lands for bioequivalence testing and generic product registration IFaB as a choice for your trials in Mexico and Brazil
Marlene Teresa Llopiz-Aviles, Harvard University School of Public Health, USA

Panel Discussion

Day 2 August 18, 2015

Hall-2

Track 2: Bioanalytical Methodology
Track 4: Regulatory Policies, Procedures and Prerequisites for Clinical Research
Track 6: Relevance of Genetics to BA/BE in Drug Development
Track 8: Advances in Assessment of Bioequivalence
Track 10: Metabolic Pathways and Changes in Nutrient Bioavailability

Session Chair: Subrata Deb, Roosevelt University College of Pharmacy, USA
Session Co-Chair: Dongmei Zhao, Shenyang Pharmaceutical University, China

Session Introduction

Title: Effect of formulation development and API characteristics on fast dissolving dosage forms bioequivalence studies
Gulay Yelken Demirel, Sanovel Pharmaceuticals, Turkey

Title: Oral bioavailability and gender-related pharmacokinetics of Celastrol following administration of pure celastrol and its related tablets in rats
Wenzheng Ju, Jiangsu Provincial Hospital of Traditional Chinese Medicine, China

Title: Preparation and *in-vitro* evaluation of meloxicam co-ground mixtures
Aly H Nada, Kuwait University, Kuwait

Networking & Refreshments

Title: Impact of glucocorticoids on the bioavailability and metabolism of Abiraterone and Calcitriol
Subrata Deb, Roosevelt University College of Pharmacy, USA

Title: Comparative analysis, target specicities and plant protection potential of antimicrobial peptides isolated from *xenorhabdus* species
Andras Fodor, University of Wisconsin-Madison, USA

Lunch Break

Title: E-BABE- A bioequivalence study of two Nicotine 2mg Lozenge formulations in healthy adult Indian human male smoker subjects
Muneesh Garg, Sitec Labs Pvt Ltd, India

Title: Eprosartan mesylate cocrystals and their enhanced oral bioavailability studies
Jaswanth Santosh Bhandaru, Kakatiya University, India

Title: *In-vitro* bioequivalence studies in tablet formulation containing 625mg of Colesevelam hydrochloride
Gulcin Tok, Sanovel Pharmaceuticals, Turkey

Poster Presentations

BA-001 **Title: A rapid HPLC method for metoprolol quantification: Application for *ex vivo* intestinal studies using Franz cells**
Andre Bersani Dezani, University of Sao Paulo, Brazil

BA-002 **Title: A rapid HPLC method for ranitidine quantification: Application for *in situ* intestinal perfusion studies**
Thaisa Marinho Dezani, University of Sao Paulo, Brazil

BA-003 **Title: Patchable thermal responsive ion channel for drug delivery**
Kyoung-Yong Chun, Korea University, Republic of South Korea

BA-004 **Title: *In-vitro* bioequivalence studies in tablet formulation containing 625mg of colesevelam hydrochloride**
Gulcin Tok, Sanovel Pharmaceuticals, Turkey

BA-005 **Title: E-BABE- A bioequivalence study of two Nicotine 2mg Lozenge formulations in healthy adult Indian human male smoker subjects**
Muneesh Garg, Sitec Labs Pvt Ltd, India

BA-006 **Title: Eprosartan mesylate cocrystals and their enhanced oral bioavailability studies**
Jaswanth Santosh Bhandaru, Kakatiya University, India

BA-007 **Title: *In-vitro* bioequivalence study of Tiotropium bromide inhaled drug emitted from Spiriva and Tiova formulations**
Abdullah Alturki, King Abdullah International Medical Research Centre, KSA

BA-008 **Title: *In-vitro* bioequivalence study of Tiotropium bromide inhaled drug emitted from Spiriva and Tiova formulations**
Salman Abdullah Alfadhel, King Abdullah International Medical Research Centre, KSA

Networking & Refreshments

Panel Discussion

Day 3 August 19, 2015

Hall-2

Introduction

Business to Business Meetings(B2B)

Networking & Refreshments Break

Academics & Research Meetings

Networking & Lunch Break

Closing Ceremony

Day 1 September 29, 2014

Registrations

Anna Polis

Opening Ceremony

Keynote Forum

Introduction

Sinerik Ayrapetyan
UNESCO, Armenia

Michael Retsky
Harvard School of Health, USA

Georg F Weber
University of Cincinnati Academic Health Center, USA

Coffee Break

Sid Bhoopathy
Absorption Systems, USA

Track 1: Emerging Bioavailability and Bioequialence Studies
Track 2: Bioanalytical Methodology

Session Introduction

Session Chair: Sinerik Ayrapetyan, UNESCO, Armenia
Session Co-Chair: Yahdiana Harahap, University of Indonesia, Indonesia

Title: Novel approach to enhance oral bioavailability of drugs with poor permeability
Michael Zhuo Wang, University of Kansas, USA
Title: Reversible metabolic complexes for novel drug discovery
Songon An, University of Maryland, Baltimore County, USA
Title: Strategies for establishing equivalence of complex drug products
Sid Bhoopathy, Absorption Systems, USA
Title: Renal elimination of aristolochic acid I in the isolated perfused kidney model
Mariana Babayeva, Touro College of Pharmacy, USA
Title: A bioequivalence study of quetiapine film coated tablets in Indonesian volunteers
Yahdiana Harahap, University of Indonesia, Indonesia

Lunch Break

Title: Intracellular water absorption is a primary sensor for extracellular and intracellular signals
Sinerik Ayrapetyan, UNESCO, Armenia
Title: Expanding BCS-based biowaivers
Lisa J Murray, Provenir, USA
Title: Impact of rHu-Epo supplementation on CRF induced neurobehavioral changes in rats: Studies on correlation with APP ratio, β amyloid and pTau expression
P Venkataraman, SRM Medical College, India
Title: Synergism of antibiotics and plant extracts in antibacterial activity against methicillin resistant *Staphylococcus aureus*
Jency Blesson, Sree Buddha College of Engineering, India
Title: Analytical techniques for tracking counterfeit and substandard medicines
Badr Aljohani, Queen Mary University of London, UK
Title: Micrometer-sized giant vesicles composed of amphiphilic random block copolymers prepared by photopolymerization-induced self-assembly
Eri Yoshida, Toyohashi University of Technology, Japan

Coffee Break

Title: Determination of clarithromycin in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry application to bioequivalence studies
Syed N Alvi, King Faisal Specialist Hospital & Research Centre, Saudi Arabia
Title: The challenge of nanomaterial and environmental bioavailability (NEB) measures
Camellia Moses Okpodu, Norfolk State University, USA

Cocktails Sponsored by **Journal of Bioequivalence & Bioavailability @ Foyer**

Day 2 September 30, 2014

Anna Polis

Keynote Forum

Jim Jingjun Huang
Ascendia Pharmaceuticals, USA

P Venkataraman
SRM Medical College, India

Track 3: Contemporary Challenges of Drug Design, Discovery and Development
Track 6: Relevance of Genetics to BA/BE in Drug Development
Track 7: Bioavailability, Bioequivalence and Drug Product Selection
Track 10: Metabolic Pathways and Changes in Nutrient Bioavailability

Session Chair: Dongfeng Tan, The University of Texas MD Anderson Cancer Center, USA
Session Co-Chair: P Venkataraman, SRM Medical College, India

Title: Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents
Ming-Hua Hsu, National Tsing Hua University, Taiwan

Coffee Break

Title: *In vitro*/*in vivo* correlation of fast release mephenamic acid microspheres in humans
Aly H Nada, Kuwait University, Kuwait
Title: Functional Respiratory Imaging (FRI) to assess bio-equivalence of inhaled medication
Jan De Backer, FLUIDDA, Belgium
Title: Design of drug delivery system for poorly water soluble drugs with enhanced bioavailability
Jim Jingjun Huang, Ascendia Pharmaceuticals, USA
Title: Biobanking and its role in precision medicine
Dongfeng Tan, The University of Texas MD Anderson Cancer Center, USA
Title: BCS-Based biowaivers: Which drugs are eligible?
Anita Nair, Merck KGaA, Germany
Title: Simulating the suppression of mechanism for the pathogenic *E.coli* resistance to gentamicin
I S Korotetskiy, Scientific Centre for Anti-Infectious Drugs, Kazakhstan

Lunch Break

Title: Plant medicine and veterinary potential of antimicrobial peptides produced by entomopathogenic nematode symbiotic bacteria
Habil Andras Fodor, Ohio State University, USA
Title: Chemical degradation of proteins: Novel pathways and products probed during accelerated stability studies
Christian Schoneich, The University of Kansas, USA
Title: Development of curcumin solid lipid nanoparticle and assessment of pharmacokinetics and brain availability in Wistar rats
Habibur Rahman, PSG College of Pharmacy, India
Title: Chemical modification of anticancer parasporins for decreasing of their toxicity
Almas Okassov, Scientific Center for Anti-Infectious Drugs, Kazakhstan
Title: Formulation and evaluation of esomeprazole buccal patch
Harsh Shah, Shankersinh Vaghela Bapu Institute of Pharmacy, India
Title: Pharmacogenomics of cancer therapeutics: Molecular structure, drug development and inter-patient variability
Salah M Blaih, Kent State University, USA

Coffee Break

Title: Control and treatment of ehrlich tumors implanted in mice by extremely low frequency electromagnetic waves at resonance frequency
Fadel M Ali, Cairo University, Egypt
Title: Na,K-ATPase isoform-selective cardiac glycosides: A potential anti-cancer drug?
Adriana Katz, Weizmann Institute of Science, Israel
Title: Pharmacokinetics of anti-tuberculosis drug on healthy volunteers: Results from the phase I clinical trial
Rinat Islamov, Scientific Center for Anti-Infectious Drugs, Kazakhstan
Title: Efficiency of two-stage designs for crossover bioequivalence trials
Sven Schnaidt, University of Heidelberg, Germany

Poster Presentations @ Foyer

Cocktails Sponsored by **Journal of Bioanalysis & Biomedicine @ Foyer**

Day 3 October 01, 2014

Anna Polis

Track 9: Need for Conducting BA/BE Studies
Track 12: Clinical Pharmacology and Therapeutics
Track 13: Translational Cancer Research and Anti Cancer Drug Discovery

Session Introduction

Session Chair: John P Marino, National Institute of Standards and Technology, USA
Session Co-Chair: Sungchul Ji, Rutgers University, USA

Title: BABE is a beautiful science but why is it only infrequently used in oncology?
Michael Retsky, Harvard School of Public Health, USA

Title: Clinical outcome in patients with cardiovascular pathologies treated with clopigogrel: Impact of genotype profile, clopidogrel metabolites PK and comedication on the clinical results
Luigi Silvestro, 3S-Pharmacological Consultation & Research GmbH, Germany

Title: Mathematical models of RNA expression profiles: Potential applications to drug discovery research and personalized medicine
Sungchul Ji, Rutgers University, USA

Title: Evaluation of the adhesion performance of different transdermal formulations by means of thermography in comparison with the classical visual approach as proposed by FDA
Simona Rizea Savu, 3S-Pharmacological Consultation & Research GmbH, Germany

Title: High-resolution NMR as a higher order structure assessment tool for protein therapeutics
John P Marino, National Institute of Standards and Technology, USA

Coffee Break

Title: Pharmacokinetics and pharmacodynamics of thymoquinone as a novel agent in sepsis management
Khalid M Alkharfy, King Saud University, Saudi Arabia

Title: Cancer characteristics that may compromise drug efficacy
Georg F Weber, University of Cincinnati Academic Health Center, USA

Title: Assessing the bioavailability and bioequivalence of topical dermatologic drug products with multiple surrogate tests
Thomas J Franz, Cetero Research, USA

Title: Effects of carbamazepine on serum levels of folic acid and homocysteine
Hasan Khaled, Damascus University, Syria

Title: Role of Na,K-ATPase in human pancreatic and liver cancer
Peiying Yang, The University of Texas, USA

Title: Isoeugenol accelerates wound healing by attenuating pro-inflammatory markers and chemokine expression in diabetic mice
Tajdar Husain Khan, Salman Bin Abdulaziz University, Saudi Arabia

Lunch Break @ Eden's Landing Restaurent

